Literature Collection

PURPOSE: The New Mexico P5 (Physician-Pharmacist-Patient-Payor Partnerships) Summit, held May 13-15, 2024, in Albuquerque, NM, sought to bring physicians, pharmacists, patients, and payors together to address the state's healthcare access crisis by advancing integration of advanced practice pharmacists (APPh) into team-based care. The summit sought to identify gaps in healthcare delivery, optimize pharmacists' clinical roles, and develop sustainable collaborative care models to improve outcomes, particularly in rural and underserved areas. SUMMARY: New Mexico has a long history of progressive pharmacy practice legislation, including the Pharmacist Prescriptive Authority Act (1993) and reimbursement parity for pharmacist-provided services (2020). The New Mexico P5 Summit convened 119 stakeholders-healthcare providers, payors, policymakers, employers, and patient advocates-to address primary care shortages, workforce gaps, and socioeconomic determinants of health. Keynote and panel sessions examined APPh models in New Mexico and other states, payment reform initiatives, and expanded pharmacist roles in chronic disease management, preventive care, and point-of-care testing. Breakout sessions identified 5 priority areas: (1) legislative and regulatory reform, (2) pharmacy workforce development, (3) health information exchange, (4) reimbursement/business models for clinical services, and (5) employer-based pharmacist demonstration projects. Workgroups were formed and are working to address these priorities. CONCLUSION: The New Mexico P5 Summit underscored the potential of APPh to mitigate primary care shortages and improve healthcare quality, access, and equity. The collaborative strategies and workgroup initiatives developed provide a framework for legislative, workforce, and payment reforms that leverage pharmacists' expertise. Ongoing stakeholder engagement will be essential to achieving sustainable innovations and transforming New Mexico's healthcare delivery system.

The treatment and support of people experiencing gambling-related harms is currently provided by a combination of a small number of specialist NHS clinics, private healthcare providers, voluntary and third sector providers, and some primary care gambling services with specialist GP input. The majority of these services have developed to respond to local and national demand with a lack of coordinated commissioning arrangements or agreed referral pathways. This lack of coordination and clear referral pathways may lead to inconsistencies in the ability to access treatment, whereby some people cannot or do not know how and where to access the help and support they need. In addition, people experiencing gambling-related harms may require support from mental health or substance use services, that complements the treatments offered for their gambling, and so it is important that integration of treatment services is considered. With the planned and ongoing expansion of NHS clinics there is an opportunity as part of the development of this guideline to create a more coherent and connected service, with a standardised governance structure. The aim of this review is to determine if there is evidence to support any care pathways or models of care for people experiencing gambling that harms.

BACKGROUND: Prescribing medication for opioid use disorder (MOUD) in primary care helps meet treatment demand, but few studies examine long-term treatment retention among medically-underserved primary care patients. METHODS: This 9-year retrospective study assessed overall retention at 6 months, and yearly up to 9 years, among 1451 patients with at least 6 months of buprenorphine prescription data from a federally-qualified health center (FQHC). We also examined whether patients who had gaps in treatment (>14 days without medication) later returned to care. Associations with treatment retention over total time in care were assessed. RESULTS: On average, patients received buprenorphine treatment for 2.26 years. Among patients who experienced gaps in treatment but returned to care within 90 days, 64% were still receiving buprenorphine at six months (n=930 of 1451), and 70% (n =118 of 169) at 9 years, with an average yearly interval retention of 69% (range: 58-74%). Patients were on MOUD treatment and not in a gap about 81% of the time, and averaged 1.0 gap per patient per year (SD: 1.09; range 0-7.87). The mean gap length over the treatment period was 33.16 days. Older age, higher percentages of negative opioid tests, negative cocaine tests, and positive buprenorphine tests, and having diabetes were associated with longer treatment retention. CONCLUSIONS: Opioid use disorder (OUD) can be treated successfully in primary care FQHCs. Treatment gaps are common and reflect the chronic relapsing nature of OUD.